Ghiselli Roberto, Giacometti Andrea, Cirioni Oscar, Mocchegiani Federico, Orlando Fiorenza, Kamysz Wojciech, Del Prete Maria Simona, Lukasiak Jerzy, Scalise Giorgio, Saba Vittorio
Institute of Infectious Diseases and Public Health, University of Ancona, Italy.
J Vasc Surg. 2002 Nov;36(5):1027-30. doi: 10.1067/mva.2002.127530.
The purpose of this study was to investigate the efficacy of temporin A as a prophylactic agent in a rat model of vascular graft infection from methicillin sodium-susceptible and methicillin sodium-resistant Staphylococcus epidermidis.
The prospective, randomized, controlled animal study set in a research laboratory in a university hospital used 280 adult male Wistar rats (weight range, 280 to 350 g). Graft infections were established in the back subcutaneous tissue of rats with implantation of 1-cm(2) sterile Dacron grafts followed by topical inoculation with 2 x 10(7) colony-forming units of S epidermidis. The study for each staphylococcal strain included: one control group (no graft contamination), one contaminated group that did not receive any antibiotic prophylaxis, one contaminated group that received temporin A-soaked graft, two contaminated groups that received perioperative intraperitoneal cefazolin (30 mg/kg) or vancomycin hydrochloride prophylaxis (10 mg/kg), and two contaminated groups that received temporin A-soaked graft and perioperative intraperitoneal cefazolin (30 mg/kg) or vancomycin hydrochloride (10 mg/kg) prophylaxis. All grafts were explanted at 7 days after implantation. The main outcome measure was quantification of bacterial contamination.
Overall, the perioperative prophylaxis based on soaked grafts was not significantly different to that of parenteral vancomycin hydrochloride. Only the combination between temporin A and vancomycin hydrochloride produced a complete bacterial inhibition for both strains.
Temporin A showed a similar antibacterial in vitro activity against the two different strains. The in vivo results suggest its potential use in providing prophylaxis to direct graft contamination when used in combination with parenteral vancomycin hydrochloride.
本研究旨在探讨天蚕素A作为预防剂在对甲氧西林敏感和耐甲氧西林表皮葡萄球菌引起的血管移植物感染大鼠模型中的疗效。
这项前瞻性、随机、对照动物研究在大学医院的研究实验室进行,使用了280只成年雄性Wistar大鼠(体重范围为280至350克)。通过植入1平方厘米的无菌涤纶移植物,然后在大鼠背部皮下组织接种2×10⁷表皮葡萄球菌菌落形成单位,建立移植物感染模型。针对每种葡萄球菌菌株的研究包括:一个对照组(无移植物污染),一个未接受任何抗生素预防的污染组,一个接受浸泡过天蚕素A的移植物的污染组,两个接受围手术期腹腔注射头孢唑林(30毫克/千克)或盐酸万古霉素预防(10毫克/千克)的污染组,以及两个接受浸泡过天蚕素A的移植物并接受围手术期腹腔注射头孢唑林(30毫克/千克)或盐酸万古霉素(10毫克/千克)预防的污染组。所有移植物在植入后7天取出。主要观察指标是细菌污染的定量分析。
总体而言,基于浸泡移植物的围手术期预防与肠胃外注射盐酸万古霉素的预防效果无显著差异。只有天蚕素A与盐酸万古霉素联合使用对两种菌株均产生了完全的细菌抑制作用。
天蚕素A对两种不同菌株显示出相似的体外抗菌活性。体内结果表明,当与肠胃外注射盐酸万古霉素联合使用时,它有预防移植物直接污染的潜在用途。